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Abstract
Background: Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are two distinct but closely
related entities with strong morphologic and genetic similarities. While chRCC is a malignant tumor, oncocytoma is
usually regarded as a benign entity. The overlapping characteristics are best explained by a common cellular origin,
and the biologic differences between chRCC and oncocytoma are therefore of considerable interest in terms of
carcinogenesis, diagnosis and clinical management. Previous studies have been relatively limited in terms of
examining the differences between oncocytoma and chromophobe RCC.
Methods: Gene expression profiling using the Affymetrix HGU133Plus2 platform was applied on chRCC (n = 15) and
oncocytoma specimens (n = 15). Supervised analysis was applied to identify a discriminatory gene signature, as well
as differentially expressed genes. High throughput single-nucleotide polymorphism (SNP) genotyping was performed
on independent samples (n = 14) using Affymetrix GeneChip Mapping 100 K arrays to assess correlation between
expression and gene copy number. Immunohistochemical validation was performed in an independent set of
tumors.
Results: A novel 14 probe-set signature was developed to classify the tumors internally with 93% accuracy, and
this was successfully validated on an external data-set with 94% accuracy. Pathway analysis highlighted clinically
relevant dysregulated pathways of c-erbB2 and mammalian target of rapamycin (mTOR) signaling in chRCC, but no
significant differences in p-AKT or extracellular HER2 expression was identified on immunohistochemistry. Loss of
chromosome 1p, reflected in both cytogenetic and expression analysis, is common to both entities, implying this
may be an early event in histogenesis. Multiple regional areas of cytogenetic alterations and corresponding
expression biases differentiating the two entities were identified. Parafibromin, aquaporin 6, and synaptogyrin 3
were novel immunohistochemical markers effectively discriminating the two pathologic entities.
Conclusions: Gene expression profiles, high-throughput SNP genotyping, and pathway analysis effectively
distinguish chRCC from oncocytoma. We have generated a novel transcript predictor that is able to discriminate
between the two entities accurately, and which has been validated both in an internal and an independent data-set,
implying generalizability. A cytogenetic alteration, loss of chromosome 1p, common to renal oncocytoma and chRCC
has been identified, providing the opportunities for identifying novel tumor suppressor genes and we have identified
a series of immunohistochemical markers that are clinically useful in discriminating chRCC and oncocytoma.
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Epithelial renal cell carcinoma (RCC) is the most common
malignancy of the adult kidney. RCC is a clinicopathologi-
cally heterogeneous disease that is traditionally classified
by morphology into clear cell, papillary, chromophobe,
and collecting duct carcinoma. Chromophobe renal cell
carcinoma (chRCC) and renal oncocytoma are two distinct
but related entities, with strong morphologic and genetic
similarities [1]. Distinguishing between the two tumors
may present a significant diagnostic challenge on routine
hematoxylin-eosin stained sections, especially in cases
with features resembling both chRCC and oncocytoma,
oncocytoma with associated invasion and even metastasis
[2], and the eosinophilic variant of chRCC.
ChRCCs account for about 4-8% of all renal tumors,
with a more favorable prognosis relative to clear cell renal
cell carcinoma, which comprises the majority of all RCCs
[3]. On the other hand, oncocytoma is the most common
benign renal tumor, comprising 5-8% of resected renal
masses. The overlapping characteristics of these entities
may be explained by a possible common origin from the
intercalated cells of the distal tubule [4]. Patients with
Birt-Hogg-Dubé syndrome, a familial multi-tumor syn-
drome linked to mutation of the BHD gene, exhibit bilat-
eral oncocytomas, chRCC and hybrid tumors [5,6].
In our previous gene expression profiling studies of a
limited number of chRCC and oncocytoma [7], we
demonstrated that both tumors showed strong similari-
ties in expression patterns suggesting a common underly-
ing biology [8] and this was supported by subsequent
expression profiling studies by other groups [9]. We
hypothesized that more effective discrimination might be
achieved with a larger sample number with additional
analyses, and that the differences might shed light on the
underlying genetic drivers of tumorigenesis, diagnosis
and clinical management. We set out to perform a com-
prehensive characterization of both entities by integrating
gene expression and high resolution single-nucleotide
polymorphism (SNP) profiling, proceeding to identify a
useful and valid molecular predictor, as well as identify-
ing novel immunohistochemical markers for each entity.
Methods
Gene expression profiles
A total of 30 frozen primary kidney tumors (15 chRCC
and 15 oncocytomas) were obtained from the French
Kidney Tumors Consortium, University of Chicago,
Northwestern University, and Spectrum Health Hospital
(Grand Rapids, MI). Each sample was confirmed by
pathologic analysis and anonymized prior to the study.
A portion of the tumor sample was frozen in liquid
nitrogen immediately after surgery and stored at -80°C.
Total RNA was isolated from the frozen tissues using
Trizol reagent (Invitrogen, Carlsbad, CA) and purified
using the RNEasy kit (Qiagen). Gene expression profil-
ing was performed as previously described using the
HGU133 Plus 2.0 Affymetrix GeneChip platform, with
54,675 distinct transcripts assayed [10]. An external
GEO data-set of gene expression profiles of oncocyto-
mas and chRCC from Cornell University was obtained
for validation (GSE12090) [11]. Data for this study has
been uploaded publicly in the Gene Expression Omni-
bus, with the accession number GSE19982.
DNA single-nucleotide polymorphism (SNP) arrays
DNA from an independent set of 6 chRCC and 8 onco-
cytomas obtained from the Cooperative Human Tissue
Network were isolated using a Jetquick DNA extraction
kit (Genomed, Lohne, Germany) according to the manu-
facturer’s protocol. The SNP assay was performed
according to the manufacturer’s instructions using the
Affymetrix GeneChip Mapping 100 K array (Affymetrix,
Santa Clara, CA). The raw SNP array data was pro-
cessed by Affymetrix GeneChip Genotyping analysis
(GTYPE v.3) and human genome reference of NCBI
build 36 was used for analysis.
Statistical analyses for expression data
Statistical analyses were performed in the statistical envir-
onment R 2.6.0, utilizing packages from the Bioconductor
project [12]. The robust multichip average (RMA) algo-
rithm was used to perform pre-processing of the CEL files,
including background adjustment, quartile normalization
and summarization. For purposes of hierarchical analysis
using complete linkage analysis, probe set filtering for
coefficient of variation (≥0.05, with at least 2 samples
showing log2 value expression of 8) was performed. Signif-
icance analysis of microarrays (SAM) on unfiltered data
based on two-class unpaired analysis, assumption of
unequal group variances and 10,000 permutations was
used to derive a list of probe sets differentially expressed
between tumor subclasses, and ordered by relative fold-
change [13]. A maximum false discovery rate threshold
was defined as 0.05.
For derivation of a small gene classifier, we used pre-
diction analysis of microarrays (PAM), an R implemen-
tation of nearest shrunken centroids methodology with
10-fold cross validation over 100 gene thresholds and an
offset percentage of 30% on unfiltered data [14]. A max-
imum acceptable cross-validated misclassification error
was defined as ≤ 10%. The smallest predictor corre-
sponding to this cross-validated error was selected for
external validation. We inferred cytogenetic profiles for
the tumors through the use of a refinement of the com-
parative genomic microarray analysis (CGMA) algorithm
[15], which predicts chromosomal alterations based on
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Page 2 of 12regional changes in expression. Briefly, relative expres-
sion profiles R were generated from the single channel
tumor expression profiles (T)a n dt h em e a ne x p r e s s i o n
values of 12 single channel cortical kidney expression
profiles (N) such that R = log2(T) - log2(N).
Pathway analysis
KEGG pathway and gene ontology (GO) analysis of
enriched gene sets was performed using hypergeometric
tests available in the GOstats package in Bioconductor
after having identified unique genes with corresponding
annotations. For KEGG pathway analysis, the p-value
threshold was 0.01. For GO analysis, conditional testing
was performed, and the threshold for p was 0.001.
Molecular function, biologic process, and cellular com-
ponent analyses were performed.
DNA copy number analysis
DNA copy number (CN) was calculated based on the
allele intensity of each SNP probe on the array using
dChip [16]http://biosun1.harvard.edu/complab/dchip/.
Information about the cytobands and the physical position
of all SNPs was obtained from Affymetrix and UCSC gen-
ome bioinformatics database (NCBI Build 36.1) http://gen-
ome.ucsc.edu. The working criteria for loss or gain are
defined as the chromosomal region with at least four con-
secutive SNPs with CN < 1.6, or at least four consecutive
SNPs with CN > 3.5, respectively. Copy number alteration
(CNA) regions were identified when more than 30% of the
samples showed copy number loss or gain.
Immunohistochemistry
Immunohistochemical staining was performed on an
independent set of chRCC (n = 11) and oncocytomas
(n = 7). Aquaporin 6 and synaptogrin 3 were selected
from the PAM (Table 1). Parafibromin (218578_at)
(2-fold expression difference) and cytokeratin 7
(209016_s_at) were selected from the SAM analysis of
t h eg e n ee x p r e s s i o np r o f i l e sfor validation. Candidate
marker choice was determined by factors including
fold-change, specificity, biological and clinical interest.
CK7 was selected as a marker to ascertain the addi-
tional benefit of routine pathologic practice in the
samples. Briefly, following blocking and antigen retrie-
val, 4-micron sections on coated slides were incubated
with the following antibodies: a mouse anti-cytokeratin
7 monoclonal antibody (DakoCytomation, Carpinteria,
CA, 1:50, cytoplasmic staining), a polyclonal rabbit
anti-human aquaporin 6 (AQP6, Alpha Diagnostic
International, San Antonio, TX, 1:100, overnight at
4°C, membranous staining), polyclonal goat anti-synap-
togyrin 3 N-18 and C-18 antibodies (SYNGR3, Santa
Cruz Biotechnology, Santa Cruz, CA, cytoplasmic and
membranous staining), a mouse monoclonal antibody
specific for parafibromin (1:250, 1 hour at room tem-
perature, nuclear staining) [17], a rabbit monoclonal
anti-HER2 antibody (Neomarker RM 9103-S clone
SP3, 1:200, membranous staining), a phospho-AKT
(Ser473) antibody (Cell Signaling Technology, 1:30,
cytoplasmic and nuclear staining). For the latter two
antibodies, 22 chromophobe RCC and 8 oncocytoma
specimens were available. For p-AKT, staining in the
stromal and the tumor cell compartments was sepa-
rately assessed. Subsequent reactions were performed
with biotin-free HRP enzyme labeled polymer of EnVi-
sion Plus detection system (DakoCytomation). All
slides were examined by a pathologist in a blinded
fashion.
Table 1 Predictor derived via nearest shrunken centroid method for sample classification of chromophobe RCC and
oncocytoma
Affymetrix Probe ID Gene description ChRCC-score* Oncocytoma-score* Fold change**
216219_at aquaporin 6 -0.1972 0.1972 0.20
240304_s_at transmembrane channel-like 5 0.1247 -0.1247 13.0
208435_s_at aquaporin 6 -0.1218 0.1218 0.22
205691_at synaptogyrin 3 0.1108 -0.1108 3.75
230110_at mucolipin 2 -0.0731 0.0731 0.15
52940_at single immunoglobulin and toll-interleukin receptor (TIR) domain 0.0577 -0.0577 3.28
217879_at cell division cycle 27 homolog (S. cerevisiae) -0.0403 0.0403 0.
222574_s_at DEAH (Asp-Glu-Ala-His) box polypeptide 40 -0.0228 0.0228 0.48
218921_at single immunoglobulin and toll-interleukin receptor (TIR) domain 0.0205 -0.0205 3.16
1557137_at transmembrane protein 17 -0.0178 0.0178 0.40
230644_at leucine rich repeat and fibronectin type III domain containing 5 0.0172 -0.0172 4.90
223087_at enoyl Coenzyme A hydratase domain containing 1 -0.0167 0.0167 0.42
203039_s_at NADH dehydrogenase (ubiquinone) Fe-S protein 1 -0.0093 0.0093 0.46
202502_at acyl-Coenzyme A dehydrogenase -0.0089 0.0089 0.35
* A class discriminant score derived from nearest shrunken centroids methodology.
** Fold change of gene expression in chRCC relative to oncocytoma
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Gene expression profiling
We visualized the 30 expression profiles of chRCC and
oncocytoma by hierarchical clustering upon a filtered
data-set of 8,995 transcripts. Clear partitioning of the two
entities into separate classes was observed (Figure 1).
PAM yielded excellent cross-validated discrimination
over a series of thresholds [Additional file 1: Figure S1].
A gene predictor comprising 14 probe sets was identified
(Table 1), which yielded an overall accuracy of 93% in the
internal data-set (28/30) (Table 2). The same predictor
successfully classified 17 of 18 samples in the external
d a t a s e tf r o mC o r n e l lU n i v e r sity, corresponding to an
overall accuracy of 94% (Table 2). 5,210 probe sets were
found to be differentially expressed between the two enti-
ties as identified using SAM at a delta of 1.4, with a false
Figure 1 Discrimination of oncocytoma and chromophobe RCC by expression profiling. (A) A dendrogram showing an unsupervised
hierarchical cluster of the filtered data showing clustering of oncocytoma and chromophobe RCC. The color bar here separates oncocytoma (O)
from chromophobe RCC (C). (B) A heatmap of the predictor genes. Red denotes relative overexpression and blue denotes relative under-
expression. Relative parafibromin (CDC73) expression is also reported here in chromophobe RCC and oncocytoma, distinct from the 14-transcript
predictor.
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probe sets [Additional file 2: Table S1]. 2,564 number of
probe sets were relatively overexpressed in chRCC, and
2,646 transcripts relatively underexpressed in chRCC.
DNA copy number profiling and comparative genomic
microarray analysis
We report copy number gains that were detected in
chromosomes 4, 7, 11, 12, 14q, and 18q (Figure 2).
Whole chromosomal losses of chromosome 1, 2, 6, 10,
Table 2 Predictor performance in sample classification of
internal and external data-sets
Gene predictor (14 probe sets)
Predicted
chRCC
Predicted
oncocytoma
Internal Data-Set chRCC 13/15 (87%) 2/15 (13%)
Oncocytoma 0/15 (0%) 15/15 (100%)
External Data-Set chRCC 8/9 (89%) 1/9 (11%)
(Cornell) Oncocytoma 0/9 (0%) 9/9 (100%)
Figure 2 High throughput SNP analysis data in chRCC (above) and oncocytoma (below) showing multiple chromosomal copy number
alterations in chRCC, but not in oncocytoma.
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Page 5 of 1213, 17, and 21 represent a unique copy number loss
profile for chRCC. For renal oncocytoma, losses of chro-
mosome 1p were noted. A CGMA (Figure 3) derived
from the expression data yielded regional expression
biases consistent with that reported by DNA copy num-
ber profiling. We report in particular that our high
throughput methods demonstrate that there is a com-
mon gene alteration to both tumors (loss of chromo-
some 1p), which may represent an early event common
in the histogenesis of both tumors. In particular, in
oncocytoma, this loss appears restricted to the terminal
end of 1p.
Pathway Analysis
Pathway and GO analysis was performed on the SAM
analysis, demonstrating an enrichment of genes involved
in metabolic pathways in oncocytomas relative to
chRCC (Table 3). These metabolic pathways include
oxidative phosphorylation, amino acid metabolism, and
fatty acid metabolism. Conversely, high expression of
genes involved in cell adhesion, immune receptor signal-
ing as well as proliferative pathways such as c-erbB2
(Her-2/neu) and mammalian target of rapamycin
(mTOR) signaling are detected in chRCC. GO analyses
performed supported these results [Additional file 3:
Table S2], highlighting that mitochondrial genes were
highly overrepresented among genes relatively overex-
pressed in oncocytomas, whereas tight junction genes
were similarly overrepresented among genes overex-
pressed in chRCC.
Immunohistochemical findings
The immunohistochemical profiling is summarized in
Table 4 and Figure 4, the results of which were consistent
with the mRNA quantitation by microarrays. The immu-
noreactivity of chRCC to cytokeratin 7 was higher than
that of oncocytomas and normal kidney. For parafibro-
min, clear differential staining was noted, with predomi-
nantly nuclear expression in oncocytomas, and absent
expression in chRCC. For synaptogyrin-3, both N-18 and
C-18 antibodies yielded a similar signal, but the N-18
antibody yielded a crisper result though the maximal
signal was distinctly weaker compared to AQP6, for
which crisp membranous staining was noted in oncocy-
toma, but not in chRCC. For p-AKT, there was an appar-
ent, but non-significant higher immunoreactivity in
chRCC than oncocytoma, particularly in the stromal cells
relative to the tumor cells. For extracellular HER2, all
samples were unreactive (Images for p-AKT and HER2
not included).
Discussion
ChRCC and oncocytoma are morphologic and geneti-
cally related entities, and distinction between these two
tumors is important because of their different biological
behaviors. However, these entities can be difficult to
distinguish morphologically. We report the derivation of
a novel and useful gene predictor validated both on an
internal and an independent external data-set, implying
its generalizability. Our results suggest that it is possible
to classify accurately histopathologically challenging
tumors. The degree of accuracy achieved at 93%
is reasonable for a genetic classifier. However, inte-
gration into clinical practice requires a comprehensive
evaluation of these classifiers within a clinical setting,
comparing clinical outcomes in routine pathologic eva-
luation relative to that derived from novel classifiers.
This may be most practically if not most ideally done in
a retrospective fashion on paraffin-embedded tissue in a
large multi-institutional collaboration, which we are cur-
rently pursuing. This issue may become progressively
more important with the increase in incidentally
detected small tumors on radiologic surveillance, where
the dilemma between observation or intervention is
commonly posed.
Integrating RNA and DNA genomic data allows us
to verify genomic alterations in tumor samples and dis-
tinguish the genomic signatures of different tumor sub-
types. Frequent losses of chromosome 1, 2, 6, 10, 13, 17,
and 21 and gains in chromosome 4, 7, 11, 12, 14q and
18q were observed in chRCC, consistent with previously
reported data [18,19]. For renal oncocytoma, we show a
high prevalence of chromosome 1p loss. Both chromo-
phobe RCC and oncocytoma share this chromosomal
alteration, consistent with a speculation that this may
represent an early event in neoplastic transformation of
a common progenitor cell.
Chromosome 1p loss represents a common cytoge-
netic alteration in both chRCC and renal oncocytoma
identified by high-throughput SNP studies. This may
suggest that this is an early event in the histogenesis of
both tumors, before additional cellular events lead to
malignancy in lesions that progress to chRCC, similar to
chromosome 3p loss in clear cell renal cell carcinoma,
which is thought to be an early event in carcinogenesis.
Loss of chromosome 1p has been identified recently in
renal oncocytoma [20], but this has not been previously
shown to be a common cytogenetic alteration common
to both entities, which is the key insight. Our delinea-
tion of the nature of chromosome 1p loss in renal onco-
cytoma provides the opportunity to identify novel tumor
suppressor genes in future studies, and in establishing a
possible carcinogenesis progression sequence.
There has been a recent advent of targeted therapies
for a wide variety of cancers. Given the relative rarity of
chRCC, there is no current standard of care and it is
unlikely that any specific clinical trial is feasible or will
be initiated. Here, we report two clinically relevant
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Page 6 of 12Figure 3 Chromosomal ideograms derived from comparative genomic microarray analysis from expression profiles showing tumor
regional expression biases. For each ideogram, a tumor is represented by an individual vertical bar with chRCC (C) on the left and
oncocytoma (O) on the right. Red denotes an increase in predicted copy number, and blue a decrease.
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Page 7 of 12pathways–the c-erbB2/HER2 pathway and the mTOR
signaling pathway–are dysregulated in chRCC on
exploratory pathway analysis of mRNA expression, but
our evaluation of extracellular HER2 and phospho-AKT
immunohistochemical expression has not provided
direct support for this mRNA finding. On a clinical trial
level, in a subgroup analysis of a Phase III trial of
temsirolimus, an mTOR inhibitor, in poor-prognosis
RCC of all subtypes, patients of non-clear cell histology
benefited as much as patients with clear cell histology, if
not more [21]. Our findings do not permit a single defi-
nitive conclusion about the nature of pathway activation
in these two entities. Currently, mTOR inhibitors
remain a clinical standard of care for poor-risk
Table 3 Molecular pathways discriminating chRCC and oncocytoma
Pathways relatively upregulated in oncocytoma
KEGGID Pvalue OddsRatio ExpCount Count Size Term
280 0 6.206 4 17 44 Valine, leucine and isoleucine degradation
640 0 6.349 3 13 33 Propanoate metabolism
190 0 3.093 11 27 114 Oxidative phosphorylation
970 0 4.488 4 12 38 Aminoacyl-tRNA biosynthesis
20 0.001 4.833 3 9 27 Citrate cycle (TCA cycle)
330 0.001 4.032 3 10 34 Arginine and proline metabolism
4120 0.003 3.13 4 11 45 Ubiquitin mediated proteolysis
Pathways relatively upregulated in chRCC
KEGGID Pvalue OddsRatio ExpCount Count Size Term
4660 0 3.263 9 23 93 T cell receptor signaling pathway
4662 0 3.945 6 18 63 B cell receptor signaling pathway
4514 0 2.505 12 26 129 Cell adhesion molecules (CAMs)
4670 0 2.676 10 23 108 Leukocyte transendothelial migration
5220 0 3.05 7 18 76 Chronic myeloid leukemia
5212 0 2.977 7 17 73 Pancreatic cancer
4520 0.001 2.823 7 17 76 Adherens junction
5130 0.001 3.335 5 13 51 Pathogenic Escherichia coli infection - EHEC
5131 0.001 3.335 5 13 51 Pathogenic Escherichia coli infection - EPEC
4530 0.001 2.277 11 22 117 Tight junction
4664 0.001 2.65 7 16 75 Fc epsilon RI signaling pathway
4620 0.003 2.268 10 19 101 Toll-like receptor signaling pathway
4012 0.003 2.372 8 17 87 ErbB signaling pathway
564 0.003 2.621 6 14 66 Glycerophospholipid metabolism
4150 0.004 2.964 4 11 47 mTOR signaling pathway
5120 0.004 2.523 6 14 68 Epithelial cell signaling in Helicobacter pylori infection
4210 0.005 2.293 8 16 84 Apoptosis
4070 0.006 2.317 7 15 78 Phosphatidylinositol signaling system
4540 0.007 2.124 9 17 95 Gap junction
4912 0.009 2.07 9 17 97 GnRH signaling pathway
5221 0.01 2.536 5 11 53 Acute myeloid leukemia
Table 4 Results of immunohistochemical staining showing sample discrimination
chRCC Oncocytoma
Protein Positive Negative Positive Negative P-value
AQP6 3/11 (28%) 8/11 (72%) 6/7 (86%) 1/7 (14%) 0.05
Parafibromin 1/11 (9%) 10/11 (91%) 5/7 (71%) 2/7 (29%) 0.01
CK7 8/11 (72%) 3/11 (27%) 1/7 (14%) 6/7 (86%) 0.05
SYNGR3 9/11 (82%) 2/11 (18%) 0/7 (0%) 7/7 (100%) 0.002
p-AKT (stromal) 5/22 (28%) 17/22 (72%) 0/8 (0%) 8/8 (100%) 0.29
p-AKT (tumor) 13/22 (59%) 8/22 (41%) 4/8 (50%) 4/8 (50%) 0.68
Extracellular HER2 0/22 (0%) 22/22 (100%) 0/8 (0%) 8/8 (100%) NA
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Page 8 of 12Figure 4 Immunohistochemical profiling of renal oncocytoma and chromophobe RCC. (A) - (C) Hematoxylin and eosin stains of normal
cortical kidney tissue, oncocytoma and chromophobe RCC respectively; (D) - (F) Aquaporin 6 immunostaining showing membranous staining in
oncocytoma but absent staining in chromophobe RCC; (G) - (I) Parafibromin immunostaining showing strong nuclear expression in oncocytoma
and tubular epithelium but absent staining in chromophobe RCC; (J) - (L) Cytokeratin 7 immunostaining showing distinct cytoplasmic staining in
chromophobe RCC but absent staining in oncocytoma; (M) - (O) Synaptogyrin 3 immunostaining showing cytoplasmic staining in chromophobe
RCC but absent staining in oncocytoma.
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Page 9 of 12metastatic non-clear cell renal cell carcinoma. HER2
expression has been evaluated in chromophobe RCC
and oncocytoma, with distinct patterns of peptide
expression varying according to epitope [22]. Interest-
ingly, this study showed that strong intracellular HER2
expression (as defined by a 3+ expression) was strongly
expressed in chromophobe RCC (9/19) but not in onco-
cytoma (1/11), whereas neither chromophobe RCC nor
oncocytoma showed strong extracellular HER2 expres-
sion. Further evaluation of this is warranted, in conjunc-
tion with relevant fluorescent in-situ hybridization
studies.
It has been previously reported that oxidative phosphor-
ylation and energy pathway genes are overexpressed in
chRCC and renal oncocytoma relative to the other sub-
types of RCC [9]. We are able to clarify this issue, demon-
strating that even between these two entities, there are
major differences in quantitative expression of the same
pathways discriminating the two entities. Consistent with
these results, it has been recently reported that oncocyto-
mas exhibit mitochondrial DNA mutations with clonal
expansion and complex I deficiencies [23]. Oncocytoma
contains a large number of mitochondria, and the overex-
pression of these genes involved in cellular metabolism
may reflect the relative quantitative excess of the mito-
chondria. A similar profound modification in energy meta-
bolism genes has been observed in thyroid oncocytomas,
with high activity of the aerobic respiratory pathway [24].
It may be speculated that potential inhibition of autophagy
in the chromophobe RCC may correspond to this differ-
ence as well. Rohan et al have previously reported in a
smaller data-set that gene expression profiling is able to
discriminate oncocytomas and chRCC [11], and has
reported that vesicular transport and cell junction proteins
are relatively upregulated in chRCC.
In the process of validating our high-throughput expres-
sion studies, we report three novel markers discriminating
between chRCC and oncocytoma: parafibromin, aquaporin
6, and synaptogyrin 3. Parafibromin, the protein product
of the HRPT2 tumor suppressor gene, has been reported
to be downregulated in a variety of tumors [17,25],
and a role has been assigned to it in the Wnt signaling
pathway [26]. While the mechanism of parafibromin
downregulation in parathyroid carcinoma appears to be
mediated through gene mutation, this does not seem to be
the mechanism in chRCC, as we have not identified any
HRPT2 mutations after analyzing DNA samples from 5
chRCC tumors (data not shown). Similarly, other investi-
gators have reported allelic imbalances in the HRPT2 gene
in oncocytoma and chromophobe RCC, but no mutations
[27]. Aquaporin 6 is an intracellular vesicle water channel
protein reported to be expressed in the intercalated cells
of the collecting duct [28], which is hypothesized to be the
originating cell for oncocytoma and chRCC [4]. Little is
known about synaptogyrin-3, a tyrosine-phosphorylated
protein that is expressed in synaptic vesicles [29]. The rea-
sons underlying the reduced expression of aquaporin 6
and increased expression of synaptogyrin-3 in chRCC,
relative to oncocytoma are uncertain.
Conclusion
In summary, we have comprehensively characterized the
molecular profiles of chRCC and oncocytoma using high
throughput expression and SNP profiling. We have con-
sequently derived discriminating expression signatures,
pathways, cytogenetic profiles and protein markers that
are of biologic, clinical and therapeutic interest.
Additional file 1: Figure S1 - Cross validated discrimination of
oncocytoma and chromophobe RCC by PAM across a series of
thresholds. For derivation of a small gene classifier, we used prediction
analysis of microarrays (PAM), an R implementation of nearest shrunken
centroids methodology with 10-fold cross validation over 100 gene
thresholds and an offset percentage of 30%. PAM yielded excellent cross-
validated discrimination over a series of thresholds.
Additional file 2: Table S1 - Differentially expressed probe sets
between oncocytoma and chromophobe RCC. 5,210 probe sets were
found to be differentially expressed between the two entities as
identified using SAM at a delta of 1.4, with a false discovery rate of 0.03
corresponding to an estimated 222 probe sets.
Additional file 3: Table S2 - Gene ontology analyses for genes
discriminating between oncocytoma and chromophobe RCC. Gene
ontology analyses highlighting that mitochondrial genes were highly
overrepresented among genes relatively overexpressed in oncocytomas,
whereas tight junction genes were similarly overrepresented among
genes overexpressed in chRCC.
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